Australia's most trusted
source of pharma news
Monday, 20 May 2024
Posted 6 May 2024 AM
Eleven companies filed their drugs with the TGA in April - and the long, to-be-reviewed list includes a repurposed medicine for brain cancer.
The TGA has accepted Norgine's Ifinwil for the treatment of high-risk neuroblastoma (HRNB) under the FDA's Project Orbis, which provides a framework for collaborative review.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.